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Abstracts / Osteoarthritis and Cartilage 20 (2012) S54–S296S290Methods: OA patients were treated with CS (800 mg/day) or paracetamol
(4 g/day) for 6 month. Clinical examinationwas performed at baseline, and
after 1.5, 6 and 9 months of treatment, with collection of plasma and
synovial ﬂuid. The clinical examination included measurement of the
overﬂow, hypertrophy and vascularisation of the synovia as well as func-
tional study of the articulation (with Lequesne and EVA index). The levels
of CXCL16, fractalkine/CX3CL1, MCP-1/CCL-2, RANTES/CCL5 and GRO-a/
CXCL1 were determined by ELISA in the plasma and synovial samples
collected. The statistical analysis was performed with SPSS package. We
performed two different analyses. In the ﬁrst one, we studied the differ-
ence between the levels of the chemokine between each time and the
baseline. We performed this analysis in separate with the paracetamol
group and chondroitin one. For this comparison we used a non parametric
test (Wilcoxon 2 related samples test). We performed a second analysis in
order to analyze if there were differences in the chemokine levels over
time, depending on the treatment received. For this analysis an indepen-
dent sample t-test was performed.
Results: Improvements in the clinical signs of inﬂammationwere detected
after 6-9 months after CS treatment of OA patients. The comparison of the
levels of each chemokine at the different times studied versus the baseline,
indicated us that these effects were accompanied by a signiﬁcant reduction
in the synovial levels of MCP-1 at 6 month (p¼0.05), whereas in the par-
acetamol group there was a signiﬁcant increased level of RANTES
(p¼0.035). In plasma, only MCP-1 concentration was signiﬁcant dimin-
ished (p¼0.023) by CS administration. To study in global the answer to the
treatments, we perform a comparison between the effect of each drug to
the levels of each chemokine. This analysis showed us that there were
signiﬁcant differences between the response to the treatment in MCP-1, 6
month after treatment (p¼0.016), and in fractalkine, 9 month after treat-
ment (p¼0.036). In both cases the treatment with chondroitin showed
a diminution of the levels of the chemokines, while paracetamol didn't
affect in the case of MCP-1 or even increased in the case of fractalkine. All
these data show that chemokine attraction of macrophage, T-cell, eosin-
ophil and basophil is reduced with a 6 month treatment with chondroitin.
Conclusions: These results suggest that CS sulphate may represent an
adequate drug to reduce the inﬂammation associated to the OA process.
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LINKING AN ADAMTS5-SPECIFIC THERAPEUTIC MONOCLONAL
ANTIBODY TO A SENSITIVE BIOCHEMICAL MARKER OF TARGET
ENGAGEMENT AND ACTIVITY FOR POTENTIAL APPLICATION AS
A COMPANION DIAGNOSTIC
J. Larkin. GlaxoSmithKline, King of Prussia, PA, USA
Purpose: The goal of co-developing a companion diagnostic alongside
a therapeutic has distinct advantages for drug development and has
recently been suggested by some regulatory agencies to be the preferred
scenario for future approvals. The ability to identify patient subsets most
likely to respond to and beneﬁt from a treatment not only allows for
focused stratiﬁcation and reduced development costs, but also has the
potential to reduce healthcare expenditures through deﬁned treat/non-
treat guidelines. This scenario is especially useful in the context of osteo-
arthritis (OA) where the sheer patient numbers, multifactorial etiology and
unmet need of the patient population dictates an effective stratiﬁed
approach to clinical development and market acceptance.
Methods: The Target: ADAMTS5 - A Disintegrin And Metalloprotease with
ThromboSpondin motifs 5, is a key protease involved in degradation of
cartilage (aggrecan). Activity is upregulated in osteoarthritis1,2 and
inﬂammatory arthritic1,3 diseases leading to impaired joint function and
disability. Genetic loss of function is associated with cartilage protection in
preclinical disease models4-6.
The Therapeutic: A high afﬁnity humanized mAb that speciﬁcally binds
and neutralizes ADAMTS5, engages the target in vivo (cartilage), inhibits
cartilage degradation with extended duration in human OA cartilage
explant studies, and dose dependently modulates circulating ARGS neo-
epitope levels following systemic administration in cynomolgus monkeys,
supporting its potential as an OA disease modifying drug.
Results: The Diagnostic: ARGS Neoepitope - A sensitive immunoassay
capable of quantifying a speciﬁc ‘signature’ of ADAMTS5-mediated
cleavage of aggrecan in serum, plasma, urine and synovial ﬂuid withapplications for patient selection, monitoring response and potentially
efﬁcacy.
Conclusions: The Therapeutic Proﬁle: By delaying structural disease
progression, and stabilizing or improving pain and/or function, it will ﬁll
a large unmet need in joint diseases. As a chronic therapy, the safety proﬁle
will be suitable for long term administration.
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THE ESSENTIAL OIL OF ERYNGIUM DURIAEI SUBSP. JURESIANUM
INHIBITS IL-1b INDUCED NF-KB AND MAPK ACTIVATION IN HUMAN
CHONDROCYTES
A.T. Ruﬁno 1,2, C. Cavaleiro 3, F. Judas 4, L. Salgueiro 3, M.C. Lopes 1,2,
A.F. Mendes 1,2. 1Ctr. for NeuroSci. and Cell Biology, Coimbra, Portugal;
2 Faculty of Pharmacy, Univ. of Coimbra, Coimbra, Portugal; 3 Lab. of
Pharmacognosy, Faculty of Pharmacy/CEF, Univ. of Coimbra, Coimbra, Portugal;
4Univ. Hosp. of Coimbra and Faculty ofMed., Univ. of Coimbra, Coimbra, Portugal
Purpose: Intracellular signaling pathways, including NF-kB and mitogen-
activated protein kinases (MAPK), modulated by pro-inﬂammatory cyto-
kines, like IL-1b, are known to regulate several genes involved in the
inﬂammatory and catabolic processes that lead to cartilage degradation.
Therefore, these signaling intermediates are considered promising targets
for the development of anti-osteoarthritic drugs with potential disease
modifying properties. Essential oils are complexmixtures of lowmolecular
weight lipophilic molecules with favorable pharmacokinetic properties
that make them especially suited collections for drug screening. Our
previous studies showed that the essential oil isolated from the aerial parts
of Eryngium duriaei subsp. juresianum (M. Laínz) M. Laínz (an Apiaceae
species endemic in the Iberian Peninsula) reduced IL-1b-induced iNOS
expression and nitric oxide production. This work aimed at further eluci-
dating the mechanism of action of that essential oil in human chon-
drocytes, as part of a strategy to identify natural compounds with potential
disease modifying anti-osteoarthritic activity.
Methods: Knee cartilage samples (n¼5) were obtained from multi-organ
donors (23 to 67 years old, mean¼43.2) at the University Hospital of
Coimbrawith approval by the Ethics Committee. After enzymatic digestion,
cells were plated and cultured under non-proliferating conditions. C28/I2
chondrocytic cells were used in some experiments. Cells were serum
starved for 8 to 24 h and treatedwith 3 different concentrations of essential
oil solutions inDMSO for 30minbefore stimulationwith IL-1b,10ng/mL, for
5 or 30 min. The protein levels of total and phosphorylated IkBa, and
phosphorylated p38, JNK and ERK1/2MAPKwere assessed bywestern blot.
Results: In a concentration of 0.02% (v/v), the essential oil signiﬁcantly
decreased IL-1-induced phosphorylation of IkBa, JNK, p38 and ERK1/2 by
78.03.9%, 55.66.7%, 36.40.6% and 24.43.3%, respectively (p<0.001).
Even in a concentration nearly 10 fold lower (0.0025% v/v), the essential oil
still inhibited JNK and p38 phosphorylation by 21.94.48% and 23.16.11%,
respectively (p<0.05).
Conclusions: These results show that the essential oil of E. duriaei subsp.
juresianum reduces both IL-1-induced NF-kB and MAPK activation,
although it is more effective towards inhibition of NF-kB and JNK. Taken
together, the results obtained suggest that this essential oil contains
compound(s) that may present anti-inﬂammatory and anti-catabolic
properties, and thus, potential disease-modifying anti-osteoarthritic
activity. Future work will focus on the fractionation and identiﬁcation of
those compounds followed by further pharmacologic characterization.
Therapy – Surgical & Intraarticular
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10 YEAR SURVIVORSHIP OF THE MEDIAL OXFORD
UNICOMPARTMENTAL KNEE ARTHROPLASTY. A 1000 PATIENT NON-
DESIGNER SERIES - THE EFFECT OF SURGICAL GRADE AND SUPERVISON.
L. Jones, N. Bottomley, H. Pandit, D. Beard, W. Jackson, A. Price. Nufﬁeld
Dept. of Orthopaedics, Rheumatology and Musculoskeletal Sci., Oxford,
United Kingdom
Purpose: The Oxford Unicompartmental Knee Arthroplasty (OUKA) is
a well established treatment option for anteromedial gonarthrosis. The
